Only a week after the human genome was completed, Genentech Inc. downplayed the importance of genomics at its investors day meeting in New York last week. Although genomics is one of DNA's areas of research, the company believes that biology, such as cell-based assays, will continue to be the primary tool for bringing molecules to market.

Moreover, DNA does not see genomics speeding the rate of drug development, although it does envision an increase in the number of products getting to market given the discovery of more targets.